A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19
A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901
Sponsor: Medigen Vaccine Biologics Corp.
Listed as NCT04487210, this PHASE1 trial focuses on COVID-19 and remains completed. Sponsored by Medigen Vaccine Biologics Corp., it has been updated 11 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Apr 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1
-
Feb 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2020 — Oct 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Medigen Vaccine Biologics Corp.
For direct contact, visit the study record on ClinicalTrials.gov .